The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study.

In exploratory analyses, treatment with vericiguat resulted in flow-mediated dilation mean difference of 0.7%, (95% confidence interval: −1.1% to 2.5%, p = 0.40) and a nominally significant reduction of log NTproBNP of −0.42 (95% confidence interval: −0.81 to −0.04, p = 0.03).

also in 4,850 other papers

hsCRP values showed a trend favoring vericiguat treatment. hsCRP mean values decreased from 2.90 mg/L at baseline to 2.33 mg/L at 12 weeks in the vericiguat group and increased from 2.93 pm/L at baseline to 4.22 mg/L at 12 weeks in the placebo group ( Table 2 , Supplementary Figure 1 ).

also in 33,237 other papers